<DOC>
	<DOCNO>NCT01904409</DOCNO>
	<brief_summary>The primary objective study assess efficacy rifaximin SSD versus placebo prevent complication liver cirrhosis , all-cause mortality ( death due cause ) hospitalization , subject early decompensated liver cirrhosis . Rifaximin , non-systemic antibacterial agent , currently market 550 mg tablet reduction risk recurrent overt hepatic encephalopathy , complication liver cirrhosis . The rifaximin SSD tablet formulate maximize efficacy rifaximin . Subjects receive 1 5 dos rifaximin SSD tablet placebo tablet every day 24 week .</brief_summary>
	<brief_title>Dose-ranging Study Rifaximin Soluble Solid Dispersion ( SSD ) Tablets Prevention Complications Early Decompensated Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Diagnosis liver cirrhosis document ascites . Model End Stage Liver Disease ( MELD ) score least 12 , MELD Na least 12 , ChildPugh B ( score 7 9 ) . If applicable , close family personal contact provide continue oversight patient available patient conduct trial . If female childbearing potential , negative serum pregnancy test study start agree use acceptable method contraception study . History major psychiatric disorder include uncontrolled major depression control uncontrolled psychosis within past 24 month prior study start . History alcohol abuse substance abuse within past 3 month prior study start . Documented cholestatic liver disease primary sclerosing cholangitis . Had prophylactic variceal band within 2 week schedule undergo prophylactic banding study . Diagnosed infection patient currently take oral parenteral antibiotic . Significant hypovolemia , electrolyte abnormality affect mental function ( eg , serum sodium &lt; 125 mEq/L , serum calcium &gt; 10 mg/dL ) . Severe hypokalemia , define serum potassium concentration &lt; 2.5 mEq/L . Anemic , define hemoglobin concentration ≤ 8 g/dL . Renal insufficiency creatinine ≥ 1.5 mg/dL . Presence intestinal obstruction inflammatory bowel disease . Uncontrolled Type 1 Type 2 diabetes . History seizure disorder . Unstable cardiovascular pulmonary disease , categorize worsen disease condition require change treatment medical care within 30 day study start . Active malignancy within last 5 year ( exception : basal cell carcinoma skin , female , situ cervical carcinoma surgically excise ) . Has hepatocellular carcinoma . Known human immunodeficiency virus , varicella , herpes zoster , severe viral infection within 6 week study start . Positive stool test Yersinia enterocolitica , Campylobacter jejuni , Salmonella , Shigella , ovum parasite , and/or Clostridium difficile ( C. difficile ) ; determine screening period prior study start . History tuberculosis infection and/or receive treatment tuberculosis infection . History hypersensitivity rifaximin , rifampin , rifamycin antimicrobial agent , component rifaximin soluble solid dispersion . Used investigational product device , participate another research study within 30 day prior study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>